All Stories

Bristol Myers Squibb notches overall survival win with Opdivo in preoperative NSCLC

Bristol Myers Squibb has bolstered its case for Opdivo to be used as a preoperative treatment for non-small cell lung cancer (NSCLC) as it has delivered an overall survival (OS) edge when added to chemotherapy.

Feb 19, 2025 - 21:32
 0
Bristol Myers Squibb notches overall survival win with Opdivo in preoperative NSCLC
Bristol Myers Squibb has bolstered its case for Opdivo to be used as a preoperative treatment for non-small cell lung cancer (NSCLC) as it has delivered an overall survival (OS) edge when added to chemotherapy.
Read More

Tags:

Previous Article

Ionis marks 'milestone event' of Tryngolza launch with first campaigns targeting...

Next Article

Amazon to stop support for communications service Chime next year

Related Posts

Merck KGaA sets its sights on acquisition of Ogsiveo-maker SpringWorks: Reuters

Merck KGaA sets its sights on acquisition of Ogsiveo-ma...

Feb 10, 2025  0

Sanofi's versatile Qfitlia scores FDA nod to enter crowded hemophilia market

Sanofi's versatile Qfitlia scores FDA nod to enter crow...

Mar 28, 2025  0

Viking pays $150M to recruit CordenPharma for obesity drug manufacturing saga

Viking pays $150M to recruit CordenPharma for obesity d...

Mar 11, 2025  0